Trending...
- California: Three years after the end of Roe, Governor Newsom, First Partner sound the alarm on Trump's "Big, Beautiful" plan to defund Planned Parenthood - 114
- Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
- California awards over $15 million to apprenticeship programs connecting youth to high-paying jobs
What I Wish I Knew a Year Ago About the Aesthetic Market and Where I'm Investing Now
VANCOUVER, British Columbia - Californer -- In 1978, scientists isolated human insulin produced by genetically modified E. coli, marking the first biopharmaceutical derived from recombinant DNA technology. This radically new methodology for isolating enzymes and active ingredients shook biotechnology to the core, triggering a tsunami of discoveries. Since then, more than 250 therapeutic proteins and monoclonal antibodies have stolen the stage as standard of care.
In the last several years, this momentum carried over to cosmetics, as biotechnology and aesthetic medicines joined forces to isolate anti-aging skin products such as hyaluronic acid, kojic acid, and resveratrol, to name a few. But what new developments stand on the horizon? And to which direction should investors hone their gaze? Two emerging therapies, stem cell exosomes and gene therapy, scintillate brightly on the financial horizon as golden investment opportunities.
The global biotech aesthetic market size valued at USD 63.5 billion in 2021, with the compound annual growth rate (CAGR) projected to increase by 9.6% from 2022 to 2023, according to the aesthetic medicine market size report. Social distancing, sudden cuts in consumers' income levels, and temporary closures of beauty centers balanced the inevitable bottleneck in manufacturing and supply chains. The pandemic, however, saw the workforce shift to remote Zoom calls, forcing many to pay close attention to facial appearance. The market consequently saw a spike in non-invasive aesthetic treatments, with this segment dominating the market in 2021 with shares over 50%. The non-invasive aesthetic treatment market size was valued at USD 52 billion last year with a CAGR of 12.4%.
More on The Californer
Currently, 45 market competitors compose the exosome industry, with 19 of them being established companies that have recently joined the race to develop aging-defying exosome technology. Some of these companies include: Galderma S.A., Johnson & Johnson, Allergen, El. En. SpA, Alma Lasers, Cynosure, Lumenis, Solta Medical, Syneron Candela, and Merz Pharma.
Up and coming regenerative biotech company Elevai shows award winning promise with stem cell exosome topical applications as the next generation of targeted anti-aging skin care. Elevai recently won the LaunchPad SBDC People's Choice Award at the 2022 Octane Aesthetics Tech Summit ("ATS") held in Newport Beach, California, for their proprietary stem cell exosome technology and products. The Elevai platform technology illuminates potential applications in regenerative medicine and in office medical skincare treatments.
Another company worth mentioning includes Jeune, a gene-based aesthetic subsidiary of Krystal biotech, that is currently operating the first-in-human Phase 1 clinical trial of an injectable gene therapy to stimulate production of collagen type III and reduce wrinkles. The injections were well tolerated and biopsies at the injection sites showed new collagen generation, an excellent first step to directly address biological changes in the skin associated with intrinsic and extrinsic aging.
More on The Californer
Stem cell exosomes and gene therapy technologies will no doubt become the in office standard of care for regenerative and anti-aging technology, stealing the stage much in the same way that insulin radically changed diabetic care.
In the last several years, this momentum carried over to cosmetics, as biotechnology and aesthetic medicines joined forces to isolate anti-aging skin products such as hyaluronic acid, kojic acid, and resveratrol, to name a few. But what new developments stand on the horizon? And to which direction should investors hone their gaze? Two emerging therapies, stem cell exosomes and gene therapy, scintillate brightly on the financial horizon as golden investment opportunities.
The global biotech aesthetic market size valued at USD 63.5 billion in 2021, with the compound annual growth rate (CAGR) projected to increase by 9.6% from 2022 to 2023, according to the aesthetic medicine market size report. Social distancing, sudden cuts in consumers' income levels, and temporary closures of beauty centers balanced the inevitable bottleneck in manufacturing and supply chains. The pandemic, however, saw the workforce shift to remote Zoom calls, forcing many to pay close attention to facial appearance. The market consequently saw a spike in non-invasive aesthetic treatments, with this segment dominating the market in 2021 with shares over 50%. The non-invasive aesthetic treatment market size was valued at USD 52 billion last year with a CAGR of 12.4%.
More on The Californer
- California: Department of Defense agrees: it's time for Trump's militarization of Los Angeles to end
- Long Beach: City Launches Internet Service Enrollment Line
- Von Rock Law Founder Deidre Von Rock Named Super Lawyer for 2025
- California: Governor Newsom extends emergency short-term housing protections in Los Angeles
- Von Rock Law Named SFGate's Best Probate and Estate Attorney in 2025
Currently, 45 market competitors compose the exosome industry, with 19 of them being established companies that have recently joined the race to develop aging-defying exosome technology. Some of these companies include: Galderma S.A., Johnson & Johnson, Allergen, El. En. SpA, Alma Lasers, Cynosure, Lumenis, Solta Medical, Syneron Candela, and Merz Pharma.
Up and coming regenerative biotech company Elevai shows award winning promise with stem cell exosome topical applications as the next generation of targeted anti-aging skin care. Elevai recently won the LaunchPad SBDC People's Choice Award at the 2022 Octane Aesthetics Tech Summit ("ATS") held in Newport Beach, California, for their proprietary stem cell exosome technology and products. The Elevai platform technology illuminates potential applications in regenerative medicine and in office medical skincare treatments.
Another company worth mentioning includes Jeune, a gene-based aesthetic subsidiary of Krystal biotech, that is currently operating the first-in-human Phase 1 clinical trial of an injectable gene therapy to stimulate production of collagen type III and reduce wrinkles. The injections were well tolerated and biopsies at the injection sites showed new collagen generation, an excellent first step to directly address biological changes in the skin associated with intrinsic and extrinsic aging.
More on The Californer
- Long Beach to Conduct Annual Summer Recess for City Council Meetings During July
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
- Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
- Montessori Stoppani Partners with Lifetime Montessori School
- Cymbiotika Celebrates 2025 Great Place To Work Certification™
Stem cell exosomes and gene therapy technologies will no doubt become the in office standard of care for regenerative and anti-aging technology, stealing the stage much in the same way that insulin radically changed diabetic care.
Source: Braeden William Lichti
0 Comments
Latest on The Californer
- Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
- Psychologist-Turned-Hermeticist Releases Modern Guide to the Seven Hermetic Principles
- Winners Announced for Asia Pacific Business Awards 2024-2025
- Hamvay-Lang and Lampone.hu Join Forces with AIMarketingugynokseg.hu to Elevate Hungarian Lifestyle Brands on the Global Stage
- Google AI Quietly Corrects the Record on Republic of Aquitaine's Legal Sovereignty
- California: El Gobernador Newsom firma un presupuesto estatal equilibrado que reduce los impuestos a los veteranos, financia completamente las comidas escolares gratuitas, construye más viviendas y crea empleos
- California: Governor Newsom signs balanced state budget that cuts taxes for vets, fully funds free school meals, builds more housing, & creates jobs
- California: Governor Newsom announces appointments 6.27.25
- NYC Leadership Strategist Stacie Selise Launches Groundbreaking 4S Framework Series to Redefine Executive Excellence
- Baby Boomer Housing Trend: Big Homes Out, Simplicity In
- Governor Newsom slams Trump over bill that would cut millions in health coverage, food assistance for California
- Jamison & Tania Events Wins Dual California Wedding Day Magazine "Best of 2025" Awards
- California invests billions of dollars to fix roads with "gas tax," expand bus and train service
- Long Beach: City Offering Space Beach Youth Workforce Summer Camp to Inspire Next Generation of Aerospace Professionals
- Make Innovation Matter: Support H.R.1's R&D Expensing Relief for American Small Businesses
- California: Governor Newsom statement on nationwide injunctions
- City of Long Beach Facilities and Services Schedule for Independence Day
- Agreement to Supply US-Based Defense Provider with Thin-Film Solar Tech for Orbital Application; Ascent Solar Technologies, Inc. (N A S D A Q: ASTI)
- Introducing The AI Bleederboard™
- Aviator Nation Launches Exclusive MLB Capsule Collections